LONG-LIVED INSULIN DELIVERY CANNULA
Described herein are systems and methods for creating a transport tube comprising a plurality of passages configured to deliver an composition from a source into the human subcutaneous space.
1 .- 81 . (canceled)
82 . A transport tube configured to deliver a composition from a source into a subcutaneous space, the transport tube comprising:
a. a distal passageway configured to reside in the subcutaneous space comprising:
i. a distal tip, wherein the distal tip is open when it is first placed into the subcutaneous space; and
ii. a plurality of passages connecting a lumen of the transport tube with an outside surface of the transport tube, wherein the plurality of passages is configured to deliver the composition from the source into the subcutaneous space when the distal tip is occluded, thereby allowing the transport tube to reside in the subcutaneous space for at least four days; and
b. a proximal solid segment configured to reside on or above a skin surface, wherein the distal passageway and the proximal solid segment are in fluid communication.
83 . The transport tube of claim 82 , wherein the plurality of passages comprise a plurality of through-passages.
84 . The transport tube of claim 83 , wherein a through-passage of the plurality of through-passages is not in fluid communication with one another.
85 . The transport tube of claim 82 , wherein the plurality of passages comprise a plurality of interconnected passages.
86 . The transport tube of claim 85 , wherein an interconnected passage of the plurality of interconnected passages is in fluid communication with one another.
87 . The transport tube of claim 82 , wherein the composition comprises insulin.
88 . The transport tube of claim 87 , wherein the insulin comprises fast-acting insulin, intermediate-acting insulin, or long-acting insulin.
89 . The transport tube of claim 82 , wherein when the distal tip of the transport tube is occluded in the subcutaneous space, a positive pressure builds up in the lumen of the transport tube.
90 . The transport tube of claim 89 , wherein the positive pressure in the lumen of the transport tube is at least about 1 pound per square inch (PSI).
91 . A transport tube configured to deliver a composition from a source into a subcutaneous space, the transport tube comprising:
a. a distal passageway configured to reside in the subcutaneous space comprising:
i. a distal tip, wherein the distal tip is open when it is first placed into the subcutaneous space; and
ii. a plurality of passages connecting a lumen of the transport tube with an outside surface of the transport tube, wherein a passage of the plurality of passages comprises a diameter, wherein the diameter is sufficiently small to prevent a flow of the composition through the passage into the subcutaneous space when the distal tip is open, and wherein the diameter is sufficiently large to deliver the composition from the source through the passage into the subcutaneous space during an occlusion of the distal tip; and
b. a proximal solid segment configured to reside on or above a skin surface, wherein the distal passageway and the proximal solid segment are in fluid communication.
92 . A transport tube configured to deliver a composition from a source into a subcutaneous space, the transport tube comprising:
a. a distal passageway configured to reside in the subcutaneous space comprising:
i. a distal tip, wherein the distal tip is open when it is first placed into the subcutaneous space; and
ii. a plurality of passages connecting a lumen of the transport tube with an outside surface of the transport tube, wherein a wall of the distal passageway comprises an empty fraction sufficiently low to prevent a kink in the transport tube; and
b. a proximal solid segment configured to reside on or above a skin surface wherein the distal passageway and the proximal solid segment are in fluid communication.
93 . A method for delivering a composition to a subcutaneous space in a subject to treat a disease or disorder, comprising:
providing a transport tube, wherein the transport tube comprises a distal passageway configured to reside in the subcutaneous space and a proximal solid segment configured to reside on or above a skin surface, wherein the distal passageway and the proximal solid segment are in fluid communication;
inserting the transport tube into the subcutaneous space; and
delivering a sufficient amount of the composition through the transport tube into the subcutaneous space, when a distal tip of the distal passageway becomes occluded in the subcutaneous space or when the distal tip is not occluded in the subcutaneous space.
94 . The method of claim 93 , wherein the disease or disorder comprises insulin resistance.
95 . The method of claim 93 , wherein the disease or disorder comprises a Type 1 diabetes mellitus.
96 . The method of claim 93 , wherein the disease or disorder comprises a Type 2 diabetes mellitus.
97 . The method of claim 93 , further comprising replacing the transport tube at least 4 days after inserting the transport tube into the subcutaneous space.
98 . The method of claim 93 , wherein the composition comprises insulin.
99 . The method of claim 98 , wherein the insulin comprises fast-acting insulin, intermediate-acting insulin, or long-acting insulin.
100 . The method of claim 93 , wherein the composition further comprises a pharmaceutically acceptable excipient.
101 . The method of claim 100 , wherein the pharmaceutically acceptable excipient comprises phenol, cresol, a salt, a stabilizing agent, or any combination thereof.